Clinical trial
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
NCT02958969 is registered in ClinicalTrials.gov with Gregory Piazza as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
- Lead sponsor
- Gregory Piazza
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 28, 2018
- Completion date
- November 19, 2019
- Enrollment
- 50 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.